Inhibitors of PARP: Number crunching and structure gazing.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 35259019.
- Also identified by DOI 10.1073/pnas.2121979119 and PMC identifier 8931346.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SignificancePARP is an important target in the treatment of cancers, particularly in patients with breast, ovarian, or prostate cancer that have compromised homologous recombination repair (i.e., BRCA<sup>-/-</sup>). This review about inhibitors of PARP (PARPi) is for readers interested in the development of next-generation drugs for the treatment of cancer, providing insights into structure-activity relationships, in vitro vs. in vivo potency, PARP trapping, and synthetic lethality.
Medical subject headings
- Poly(ADP-ribose) Polymerase Inhibitors